Andreas U Monsch

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7990936/publications.pdf

Version: 2024-02-01

145 papers 8,851 citations

43 h-index 48315 88 g-index

174 all docs

174 docs citations

times ranked

174

12344 citing authors

#	Article	IF	CITATIONS
1	Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe. Alzheimer's and Dementia, 2022, 18, 29-42.	0.8	24
2	Genome-wide Association Study of Postoperative Cognitive Dysfunction in Older Surgical Patients. Journal of Neurosurgical Anesthesiology, 2022, 34, 248-250.	1.2	3
3	Silent brain infarcts impact on cognitive function in atrial fibrillation. European Heart Journal, 2022, 43, 2127-2135.	2.2	50
4	The Basel Version of the Awareness of Social Inference Test-Emotion Recognition (BASIT-ER): Preliminary validation analyses in healthy adults Neuropsychology, 2022, 36, 175-184.	1.3	3
5	Long-term risk of adverse outcomes according to atrial fibrillation type. Scientific Reports, 2022, 12, 2208.	3.3	5
6	Answer to "Social cognition assessment for mild neurocognitive disorders― Alzheimer's and Dementia, 2022, 18, 1441-1442.	0.8	3
7	Global brain volume and N-acetyl-aspartate decline over seven decades of normal aging. Neurobiology of Aging, 2021, 98, 42-51.	3.1	14
8	Blood Pressure and Brain Lesions in Patients With Atrial Fibrillation. Hypertension, 2021, 77, 662-671.	2.7	8
9	Insulin-like growth factor-binding protein 7 and risk of congestive heart failure hospitalization in patients with atrial fibrillation. Heart Rhythm, 2021, 18, 512-519.	0.7	7
10	Predictive value of serum neurofilament light chain for persistent cognitive deficits in elderly depressive patients. Journal of Affective Disorders Reports, 2021, 4, 100095.	1.7	1
11	Using historical data to facilitate clinical prevention trials in Alzheimer disease? An analysis of longitudinal MCI (mild cognitive impairment) data sets. Alzheimer's Research and Therapy, 2021, 13, 97.	6.2	7
12	Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2021, 20, 537-547.	10.2	55
13	Position Statement on Anti-Dementia Medication for Alzheimer's Disease by Swiss Stakeholders. Clinical and Translational Neuroscience, 2021, 5, 14.	0.9	O
14	Cats and Apples: Semantic Fluency Performance for Living Things Identifies Patients with Very Early Alzheimer's Disease. Archives of Clinical Neuropsychology, 2021, 36, 838-843.	0.5	5
15	Diagnosing foreign patients in Europe: An EADCâ€ISTAART study. Alzheimer's and Dementia, 2021, 17, .	0.8	O
16	Novel oddity detection task differentiates early Alzheimerâ \in TM s disease and major depression. Alzheimer's and Dementia, 2021, 17, .	0.8	0
17	The Neurocognitive Assessment in the Metabolic and Aging Cohort (<scp>NAMACO</scp>) study: baseline participant profile. HIV Medicine, 2020, 21, 30-42.	2.2	24
18	How helpful are the European AIDS Clinical Society cognitive screening questions in predicting cognitive impairment in an aging, wellâ€treated HIVâ€positive population?. HIV Medicine, 2020, 21, 342-348.	2.2	14

#	Article	IF	Citations
19	A factor score reflecting cognitive functioning in patients from the Swiss Atrial Fibrillation Cohort Study (Swiss-AF). PLoS ONE, 2020, 15, e0240167.	2.5	5
20	A Comparison of Serial Position Effects in Patients with Mild Cognitive Impairment due to Parkinson's Disease or to Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2020, 49, 170-178.	1.5	1
21	The context effect in facial emotion perception increases with age. Alzheimer's and Dementia, 2020, 16, e040309.	0.8	0
22	Decision-making capacity evaluations: the role of neuropsychological assessment from a multidisciplinary perspective. BMC Geriatrics, 2020, 20, 535.	2.7	4
23	Enhanced diagnostic accuracy for neurocognitive disorders: a revised cut-off approach for the Montreal Cognitive Assessment. Alzheimer's Research and Therapy, 2020, 12, 39.	6.2	49
24	Serum neurofilament light in atrial fibrillation: clinical, neuroimaging and cognitive correlates. Brain Communications, 2020, 2, fcaa166.	3.3	24
25	Measuring the Impact of Delayed Cerebral Ischemia on Neuropsychological Outcome After Aneurysmal Subarachnoid Hemorrhageâ€"Protocol of a Swiss Nationwide Observational Study (MoCAâ€"DCI Study). Neurosurgery, 2019, 84, 1124-1132.	1.1	11
26	General practitioners' attitudes towards early diagnosis of dementia: a cross-sectional survey. BMC Family Practice, 2019, 20, 65.	2.9	23
27	Cerebrospinal fluid from Alzheimer's disease patients promotes tau aggregation in transgenic mice. Acta Neuropathologica Communications, 2019, 7, 72.	5.2	16
28	Relationships of Overt and Silent Brain Lesions With Cognitive Function in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2019, 73, 989-999.	2.8	148
29	Evaluation of smartphoneâ€based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial. Movement Disorders, 2018, 33, 1287-1297.	3.9	196
30	P3â€489: GERMAN NORMATIVE DATA FOR THE MONTREAL COGNITIVE ASSESSMENT. Alzheimer's and Dementia, 2018, 14, P1309.	0.8	0
31	The Barrow Neurological Institute Grading Scale as a Predictor for Delayed Cerebral Ischemia and Outcome After Aneurysmal Subarachnoid Hemorrhage: Data From a Nationwide Patient Registry (Swiss) Tj ETQq1	1.0. 7843	1 9 9rgBT /0
32	The Montreal Cognitive Assessment: Normative Data from a German-Speaking Cohort and Comparison with International Normative Samples. Journal of Alzheimer's Disease, 2018, 64, 643-655.	2.6	74
33	Large-Scale Continuous Mobility Monitoring of Parkinson's Disease Patients Using Smartphones. Lecture Notes of the Institute for Computer Sciences, Social-Informatics and Telecommunications Engineering, 2018, , 12-19.	0.3	6
34	TOMMORROW neuropsychological battery: German language validation and normative study. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 314-323.	3.7	9
35	Facial Emotion Recognition Performance Differentiates Between Behavioral Variant Frontotemporal Dementia and Major Depressive Disorder. Journal of Clinical Psychiatry, 2018, 79, 16m11342.	2.2	22
36	Early diagnosis and management of dementia in general practice – how do Swiss GPs meet the challenge?. Swiss Medical Weekly, 2018, 148, w14695.	1.6	8

#	Article	IF	CITATIONS
37	Ginkgo biloba special extract LI 1370 improves dual-task walking in patients with MCI: a randomised, double-blind, placebo-controlled exploratory study. Aging Clinical and Experimental Research, 2017, 29, 609-619.	2.9	21
38	Associations Between Impaired Cerebral Blood Flow Autoregulation, Cerebral Oxygenation, and Biomarkers of Brain Injury and Postoperative Cognitive Dysfunction in Elderly Patients After Major Noncardiac Surgery. Anesthesia and Analgesia, 2017, 124, 934-942.	2.2	49
39	Parietal lobe critically supports successful paired immediate and single-item delayed memory for targets. Neurobiology of Learning and Memory, 2017, 141, 53-59.	1.9	6
40	Clinical validity of delayed recall tests as a gateway biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 153-166.	3.1	49
41	Human Activity Recognition from Sensor-Based Large-Scale Continuous Monitoring of Parkinson's Disease Patients. , 2017, , .		28
42	A Longitudinal Item Response Theory Model to Characterize Cognition Over Time in Elderly Subjects. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 635-641.	2.5	14
43	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurology, The, 2017, 16, 661-676.	10.2	464
44	[P2–300]: CORTICAL THICKNESS OF MEDIAL PERIRHINAL CORTEX PREDICTS VERBAL SEMANTIC FLUENCY PERFORMANCE FOR LIVING THINGS. Alzheimer's and Dementia, 2017, 13, P731.	0.8	0
45	Smartphone-based continuous mobility monitoring of Parkinsons disease patients reveals impacts of ambulatory bout length on gait features. , 2017 , , .		6
46	Use it or lose it! Cognitive activity as a protec-tive factor for cognitive decline associated with Alzheimer's disease. Swiss Medical Weekly, 2017, 147, w14407.	1.6	5
47	Design of the Swiss Atrial Fibrillation Cohort Study (Swiss-AF): structural brain damage and cognitive decline among patients with atrial fibrillation. Swiss Medical Weekly, 2017, 147, w14467.	1.6	46
48	Neuropsychological Markers of Medial Perirhinal and Entorhinal Cortex Functioning are Impaired Twelve Years Preceding Diagnosis of Alzheimer's Dementia. Journal of Alzheimer's Disease, 2016, 52, 573-580.	2.6	24
49	Older Candidates for Subthalamic Deep Brain Stimulation in Parkinson's Disease Have a Higher Incidence of Psychiatric Serious Adverse Events. Frontiers in Aging Neuroscience, 2016, 8, 132.	3.4	15
50	Dissociation in Rating Negative Facial Emotions between Behavioral Variant Frontotemporal Dementia and Major Depressive Disorder. American Journal of Geriatric Psychiatry, 2016, 24, 1017-1027.	1.2	11
51	Cortical thinning of parahippocampal subregions in very early Alzheimer's disease. Neurobiology of Aging, 2016, 38, 188-196.	3.1	49
52	The Verbal Fluency Decline After Deep Brain Stimulation in Parkinson's Disease: Is There an Influence of Age?. Movement Disorders Clinical Practice, 2016, 3, 48-52.	1.5	2
53	Association between changes in cerebral grey matter volume and postoperative cognitive dysfunction in elderly patients: study protocol for a prospective observational cohort study. BMC Anesthesiology, $2016, 16, 118$.	1.8	3
54	A longitudinal linguistic analysis of written text production in a case of semantic variant primary progressive aphasia. Journal of Neurolinguistics, 2016, 39, 26-37.	1.1	6

#	Article	IF	CITATIONS
55	"Now I see it, now I don't― Determining Threshold Levels of Facial Emotion Recognition for Use in Patient Populations. Journal of the International Neuropsychological Society, 2015, 21, 568-572.	1.8	5
56	Microstate connectivity alterations in patients with early Alzheimer's disease. Alzheimer's Research and Therapy, 2015, 7, 78.	6.2	38
57	The 12 Years Preceding Mild Cognitive Impairment Due to Alzheimer's Disease: The Temporal Emergence of Cognitive Decline. Journal of Alzheimer's Disease, 2015, 48, 1095-1107.	2.6	79
58	Varying Strength of Cognitive Markers and Biomarkers to Predict Conversion and Cognitive Decline in an Early-Stage-Enriched Mild Cognitive Impairment Sample. Journal of Alzheimer's Disease, 2015, 44, 625-633.	2.6	21
59	Considering the base rates of low performance in cognitively healthy older adults improves the accuracy to identify neurocognitive impairment with the Consortium to Establish a Registry for Alzheimer's Disease-Neuropsychological Assessment Battery (CERAD-NAB). European Archives of Psychiatry and Clinical Neuroscience. 2015. 265. 407-417.	3.2	43
60	Call for uniform neuropsychological assessment after aneurysmal subarachnoid hemorrhage: Swiss recommendations. Acta Neurochirurgica, 2015, 157, 1449-1458.	1.7	35
61	Altered cerebrovascular reactivity velocity in mild cognitive impairment and Alzheimer's disease. Neurobiology of Aging, 2015, 36, 33-41.	3.1	84
62	The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. Alzheimer's and Dementia, 2015, 11, 195.	0.8	56
63	Slowing of EEG Background Activity in Parkinsonââ,¬â"¢s and Alzheimerââ,¬â"¢s Disease with Early Cognitive Dysfunction. Frontiers in Aging Neuroscience, 2014, 6, 314.	3.4	49
64	Serum Anticholinergic Activity and Postoperative Cognitive Dysfunction in Elderly Patients. Anesthesia and Analgesia, 2014, 119, 947-955.	2.2	27
65	A common brain network links development, aging, and vulnerability to disease. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17648-17653.	7.1	268
66	Establishing robust cognitive dimensions for characterization and differentiation of patients with Alzheimer's disease, mild cognitive impairment, frontotemporal dementia and depression. International Journal of Geriatric Psychiatry, 2014, 29, 624-634.	2.7	20
67	A short tool to screen HIV-infected patients for mild neurocognitive disorders – a pilot study. BMC Psychology, 2014, 2, 21.	2.1	6
68	BrainCheck - a very brief tool to detect incipient cognitive decline: optimized case-finding combining patient- and informant-based data. Alzheimer's Research and Therapy, 2014, 6, 69.	6.2	20
69	Serial position effects are sensitive predictors of conversion from MCI to Alzheimer's disease dementia. Alzheimer's and Dementia, 2014, 10, S420-4.	0.8	36
70	Head Motion Parameters in fMRI Differ Between Patients with Mild Cognitive Impairment and Alzheimer Disease Versus Elderly Control Subjects. Brain Topography, 2014, 27, 801-807.	1.8	21
71	Global N-Acetylaspartate in Normal Subjects, Mild Cognitive Impairment and Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2014, 43, 939-947.	2.6	27
72	The Extension of the German CERAD Neuropsychological Assessment Battery with Tests Assessing Subcortical, Executive and Frontal Functions Improves Accuracy in Dementia Diagnosis. Dementia and Geriatric Cognitive Disorders Extra, 2014, 4, 322-334.	1.3	81

#	Article	IF	Citations
73	Current practice in neuropsychological outcome reporting after aneurysmal subarachnoid haemorrhage. Acta Neurochirurgica, 2013, 155, 2045-2051.	1.7	25
74	Quantitative EEG and apolipoprotein E-genotype improve classification of patients with suspected Alzheimer's disease. Clinical Neurophysiology, 2013, 124, 2146-2152.	1.5	21
75	Distinct neuroanatomical bases of episodic and semantic memory performance in Alzheimer's disease. Neuropsychologia, 2013, 51, 930-937.	1.6	72
76	O1-06-01: Challenges in international clinical trials to delay early symptomatic Alzheimer's disease. , 2013, 9, P137-P138.		4
77	Brain Microstructure Reveals Early Abnormalities more than Two Years prior to Clinical Progression from Mild Cognitive Impairment to Alzheimer's Disease. Journal of Neuroscience, 2013, 33, 2147-2155.	3.6	161
78	False positives to confusable objects predict medial temporal lobe atrophy. Hippocampus, 2013, 23, 832-841.	1.9	14
79	Neuropsychological Signs of Alzheimer's Disease 8 Years Prior to Diagnosis. Journal of Alzheimer's Disease, 2013, 34, 537-546.	2.6	43
80	Distinct neural systems underlying reduced emotional enhancement for positive and negative stimuli in early Alzheimer's disease. Frontiers in Human Neuroscience, 2013, 7, 939.	2.0	11
81	Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases. PLoS ONE, 2013, 8, e75091.	2.5	375
82	Comparison of Verbal Episodic Memory Measures: Consortium to Establish a Registry for Alzheimer's DiseaseNeuropsychological Assessment Battery (CERAD-NAB) versus California Verbal Learning Test (CVLT). Archives of Clinical Neuropsychology, 2012, 27, 510-519.	0.5	33
83	Medial perirhinal cortex disambiguates confusable objects. Brain, 2012, 135, 3757-3769.	7.6	83
84	The whole-brain N-acetylaspartate correlates with education in normal adults. Psychiatry Research - Neuroimaging, 2012, 204, 49-54.	1.8	6
85	Biomarkers of dementia: Comparison of electrochemiluminescence results and reference ranges with conventional ELISA. Methods, 2012, 56, 494-499.	3.8	10
86	Whole brain N-acetylaspartate concentration is conserved throughout normal aging. Neurobiology of Aging, 2012, 33, 2440-2447.	3.1	25
87	Plasma lipoprotein-associated phospholipase A2 activity in Alzheimer's disease, amnestic mild cognitive impairment, and cognitively healthy elderly subjects: a cross-sectional study. Alzheimer's Research and Therapy, 2012, 4, 51.	6.2	27
88	Clinical EEG in cognitively impaired patients with Parkinson's Disease. Journal of the Neurological Sciences, 2011, 310, 75-78.	0.6	17
89	DTI measures in crossing-fibre areas: Increased diffusion anisotropy reveals early white matter alteration in MCI and mild Alzheimer's disease. NeuroImage, 2011, 55, 880-890.	4.2	468
90	For debate: substituting placebo controls in long-term Alzheimer's prevention trials. Alzheimer's Research and Therapy, 2011, 3, 9.	6.2	14

#	Article	IF	Citations
91	Classification of Alzheimer's Disease from structural MRI using sparse logistic regression with optional spatial regularization., 2011, 2011, 4499-502.		20
92	Evaluation of a Summary Score of Cognitive Performance for Use in Trials in Perioperative and Critical Care. Dementia and Geriatric Cognitive Disorders, 2011, 31, 451-459.	1.5	11
93	Turning principles into practice in Alzheimer's disease. International Journal of Clinical Practice, 2010, 64, 1198-1209.	1.7	5
94	Screening properties of the German IQCODE with a two-year time frame in MCI and early Alzheimer's disease. International Psychogeriatrics, 2010, 22, 91-100.	1.0	60
95	CSF-Tau and CSF-Aβ _{1–42} in Posterior Cortical Atrophy. Dementia and Geriatric Cognitive Disorders, 2010, 29, 530-533.	1.5	31
96	An exploration of cognitive subgroups in Alzheimer's disease. Journal of the International Neuropsychological Society, 2010, 16, 233-243.	1.8	35
97	Early detection of Alzheimer's disease with a total score of the German CERAD. Journal of the International Neuropsychological Society, 2010, 16, 910-920.	1.8	79
98	Specific care program for the older adults: Memory Clinics. European Geriatric Medicine, 2010, 1, 128-131.	2.8	18
99	Drug Profile: Transdermal Rivastigmine Patch in the Treatment of Alzheimer Disease. CNS Neuroscience and Therapeutics, 2010, 16, 246-253.	3.9	25
100	Modifiable and Nonmodifiable Risk Factors for Postoperative Delirium After Cardiac Surgery With Cardiopulmonary Bypass. Journal of Cardiothoracic and Vascular Anesthesia, 2010, 24, 555-559.	1.3	118
101	Impact of APOE status on cognitive maintenance in healthy elderly persons. International Journal of Geriatric Psychiatry, 2009, 24, 132-141.	2.7	44
102	Rivastigmine for the prevention of postoperative delirium in elderly patients undergoing elective cardiac surgeryâ€"A randomized controlled trial*. Critical Care Medicine, 2009, 37, 1762-1768.	0.9	250
103	Norms for change in episodic memory as a prerequisite for the diagnosis of mild cognitive impairment (MCI) Neuropsychology, 2009, 23, 189-200.	1.3	33
104	Evaluation of diagnostic scores with adjustment for covariates. Statistics in Medicine, 2008, 27, 1777-1790.	1.6	40
105	Neuropsychological dysfunction, depression, physical disability, and coping processes in families with a parent affected by multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 1106-1112.	3.0	29
106	Clinical course of neuropathologically confirmed frontal-variant Alzheimer's disease. Nature Clinical Practice Neurology, 2008, 4, 226-232.	2.5	57
107	Clinical Characteristics of Dementia Associated with Argyrophilic Grain Disease. Dementia and Geriatric Cognitive Disorders, 2007, 24, 229-234.	1.5	14
108	Lack of Practice Effects on Neuropsychological Tests as Early Cognitive Markers of Alzheimer Disease?. American Journal of Alzheimer's Disease and Other Dementias, 2007, 22, 416-426.	1.9	50

#	Article	IF	CITATIONS
109	Topographical recognition memory sensitive to amnestic mild cognitive impairment but not to depression. International Journal of Geriatric Psychiatry, 2006, 21, 924-929.	2.7	12
110	Becoming Forgetful: How Elderly People Deal With Forgetfulness in Everyday Life. American Journal of Alzheimer's Disease and Other Dementias, 2006, 21, 347-353.	1.9	23
111	Schooling mediates brain reserve in Alzheimer's disease: findings of fluoro-deoxy-glucose-positron emission tomography. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 1060-1063.	1.9	111
112	Age-dependent effects of the 5-hydroxytryptamine-2a-receptor polymorphism (His452Tyr) on human memory. NeuroReport, 2005, 16, 839-842.	1.2	19
113	Semantic and phonemic sequence effects in random word generation: A dissociation between Alzheimer's and Huntington's disease patients. Journal of the International Neuropsychological Society, 2005, 11, 303-310.	1.8	14
114	No association of a non-synonymous PLAU polymorphism with Alzheimer's disease and disease-related traits. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 132B, 21-23.	1.7	16
115	Weight History over a Forty-Year Time Period. International Journal for Vitamin and Nutrition Research, 2005, 75, 290-296.	1.5	0
116	Assessment of everyday behavior in Alzheimer's disease patients: Its significance for diagnostics and prediction of disease progression. American Journal of Alzheimer's Disease and Other Dementias, 2005, 20, 151-158.	1.9	9
117	Frontotemporal Dementia, Semantic Dementia, and Alzheimer's Disease: The Contribution of Standard Neuropsychological Tests to Differential Diagnosis. Journal of Geriatric Psychiatry and Neurology, 2005, 18, 39-44.	2.3	83
118	Effects of galantamine on behavioural and psychological disturbances and caregiver burden in patients with Alzheimer's disease. Current Medical Research and Opinion, 2004, 20, 931-938.	1.9	20
119	Efficacy of Donepezil Treatment in Alzheimer Patients with and without Subcortical Vascular Lesions. Pharmacology, 2004, 72, 1-5.	2.2	16
120	Weight change and cognitive performance. International Journal of Obesity, 2004, 28, 1163-1167.	3.4	37
121	Argyrophilic grain disease: molecular genetic difference to other four-repeat tauopathies. Acta Neuropathologica, 2003, 106, 363-366.	7.7	17
122	Apolipoprotein E3Basel: new insights into a highly conserved protein region. European Journal of Clinical Investigation, 2003, 33, 677-685.	3.4	5
123	Identifying a cut-off point for normal mobility: a comparison of the timed 'up and go' test in community-dwelling and institutionalised elderly women. Age and Ageing, 2003, 32, 315-320.	1.6	574
124	Argyrophilic Grain Disease. Advances in Experimental Medicine and Biology, 2001, , 39-58.	1.6	19
125	Assessment of dementia in elderly outpatients: a comparative study of European centers and consensus statement. Archives of Gerontology and Geriatrics, 2000, 30, 17-24.	3.0	12
126	Apolipoprotein E allele frequencies in argyrophilic grain disease. Acta Neuropathologica, 1998, 96, 225-227.	7.7	26

#	Article	IF	Citations
127	Early Diagnosis of Dementia via a Two-Step Screening and Diagnostic Procedure. International Psychogeriatrics, 1997, 9, 123-130.	1.0	127
128	Category fluency is also predominantly affected in Swiss Alzheimer's disease patients. Acta Neurologica Scandinavica, 1997, 95, 81-84.	2.1	29
129	Argyrophilic grain disease: distribution of grains in patients with and without dementia. Acta Neuropathologica, 1997, 94, 353-358.	7.7	84
130	Screening for dementia of the alzheimer type in the community: The utility of the clock drawing test. Archives of Clinical Neuropsychology, 1996, 11, 529-539.	0.5	20
131	Random number generation in dementia of the Alzheimer type: A test of frontal executive functions. Neuropsychologia, 1996, 34, 97-103.	1.6	113
132	Screening for dementia of the alzheimer type in the community: The utility of the clock drawing test. Archives of Clinical Neuropsychology, 1996, 11, 529-539.	0.5	79
133	Neuropsychological studies of asymptomatic Human Immunodeficiency Virus-Type-1 infected individuals. Journal of the International Neuropsychological Society, 1995, 1, 304-315.	1.8	126
134	Discrimination of cortical from subcortical dementias on the basis of memory and problem-solving tests. Journal of Clinical Psychology, 1995, 51, 48-58.	1.9	59
135	Folstein vs Modified Mini-Mental State Examination in Geriatric Stroke. Archives of Neurology, 1995, 52, 477.	4.5	188
136	Episodic memory changes are associated with the APOE- epsilon 4 allele in nondemented older adults. Neurology, 1995, 45, 2203-2206.	1.1	238
137	Unawareness of Smell Loss in Normal Aging and Alzheimer's Disease: Discrepancy between Self-Reported and Diagnosed Smell Sensitivity. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 1995, 50B, P187-P192.	3.9	202
138	Clinical Validity of the Mattis Dementia Rating Scale in Detecting Dementia of the Alzheimer Type. Archives of Neurology, 1995, 52, 899.	4.5	168
139	Improving the diagnostic accuracy of the Mini-Mental State Examination. Acta Neurologica Scandinavica, 1995, 92, 145-150.	2.1	92
140	Preclinical cognitive markers of dementia of the Alzheimer type Neuropsychology, 1994, 8, 374-384.	1.3	127
141	A comparison of category and letter fluency in Alzheimer's disease and Huntington's disease Neuropsychology, 1994, 8, 25-30.	1.3	251
142	Utility of a modified version of the wisconsin card sorting test in the detection of dementia of the alzheimer type. Neuropsychology, Development and Cognition Section D: the Clinical Neuropsychologist, 1993, 7, 161-170.	1.2	44
143	Comparisons of Verbal Fluency Tasks in the Detection of Dementia of the Alzheimer Type. Archives of Neurology, 1992, 49, 1253-1258.	4.5	606
144	Safety and Effectiveness of Low-Dose Clozapine in Psychogeriatric Patients: A Preliminary Study. International Psychogeriatrics, 1992, 4, 187-195.	1.0	68

Article IF Citations

A New Behavioral Assessment Scale for Geriatric Out―and Inâ€Patients: the NOSGER (Nurses' Observation) Tj ETQq1 1 0.784314 rg